Investigations into the presence of functional ß1, ß2 and ß3-adrenoceptors in urothelium and detrusor of human bladder

International Braz J Urol

Volumn 35, Issue 1, 2009, Pages 76-82

  Tyagi, Pradeep ^a   Thomas, Catherine A ^a   Yoshimura, Naoki ^a   Chancellor, Michael B ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Adrenoreceptors; Bladder; Detrusor; Urothelium

Indexed keywords

3' ((2 ((2 (3 CHLOROPHENYL) 2 HYDROXYETHYL)AMINO)ETHYL)AMINO) (1,1' BIPHENYL) 3 CARBOXYLIC ACID; 3'-((2-((2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)ETHYL)AMINO)-(1,1'-BIPHENYL)-3-CARBOXYLIC ACID; ANILINE DERIVATIVE; BENZOIC ACID DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE; UROTHELIUM;

ADOLESCENT; ADRENERGIC BETA-1 RECEPTOR AGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANILINE COMPOUNDS; BENZOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER; UROTHELIUM; YOUNG ADULT;

EID: 67649610441     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382009000100012     Document Type: Article

References (21)

1. Andersson KE: LUTS treatment: future treatment options. Neurourol Urodyn. 2007; 26: 934-47.
2. Takeda H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O: Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther. 2000; 293: 939-45.
3. Finney SM, Andersson KE, Gillespie JI, Stewart LH: Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006; 98: 503-7.
4. Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, et al.: Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377: 437-48.
5. Frazier EP, Peters SL, Braverman AS, Ruggieri MR Sr, Michel MC: Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377: 449-62.
6. Yamaguchi O: Beta3-adrenoceptors in human detrusor muscle. Urology. 2002; 59: 25-9.
7. Igawa Y, Yamazaki Y, Takeda H, Kaidoh K, Akahane M, Ajisawa Y, et al.: Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol. 2001; 165: 240-4.
8. Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S: Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377: 473-81.
9. Murakami S, Chapple CR, Akino H, Sellers DJ, Chess-Williams R: The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int. 2007; 99: 669-73.
10. Yamaguchi O, Chapple CR: Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26: 752-6.
11. Biers SM, Reynard JM, Brading AF: The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006; 98: 1310-4.
12. Birder LA, Nealen ML, Kiss S, de Groat WC, Caterina MJ, Wang E, et al.: Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci. 2002; 22: 8063-70.
13. Pandita RK, Rønn LC, Jensen BS, Andersson KE: Urodynamic effects of intravesical administration of the new small/intermediate conductance calcium activated potassium channel activator NS309 in freely moving, conscious rats. J Urol. 2006; 176: 1220-4.
14. Ozawa H, Chancellor MB, Jung SY, Yokoyama T, Fraser MO, Yu Y, et al.: Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol. 1999; 162: 2211-6.
15. Andersson KE, Persson K: Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Urol Nephrol Suppl. 1995; 175: 43-53.
16. Masuda H, Kim JH, Kihara K, Chancellor MB, de Groat WC, Yoshimura N: Inhibitory roles of peripheral nitrergic mechanisms in capsaicin-induced detrusor overactivity in the rat. BJU Int. 2007; 100: 912-8.
17. Harmon EB, Porter JM, Porter JE: Beta-adrenergic receptor activation in immortalized human urothelial cells stimulates inflammatory responses by PKA-independent mechanisms. Cell Commun Signal. 2005; 3: 10.
18. Furuta A, Thomas CA, Higaki M, Chancellor MB, Yoshimura N, Yamaguchi O: The promise of beta3-adrenoceptor agonists to treat the overactive bladder. Urol Clin North Am. 2006; 33: 539-43.
19. Kaisary AV: Beta adrenoceptor blockade in the treatment of female urinary stress incontinence. J Urol (Paris). 1984; 90: 351-3.
20. Zinner NR, Koke SC, Viktrup L: Pharmacotherapy for stress urinary incontinence : present and future options. Drugs. 2004; 64: 1503-16.
21. Reynard JM: Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004; 14: 13-6.